We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Advanced High Throughput Screening Tools to Enter British Biotech Market

By LabMedica International staff writers
Posted on 23 Apr 2012
A major British distributor of genome and proteome research tools will now be marketing a line of microarrays for high throughput screening of drug targets such as protein kinases as well as other nucleotide-dependent enzymes targeted for therapeutic intervention.

Cambio (Cambridge, United Kingdom) will now be supplying its local and international customers with BellBrook Labs’ (Madison WI, USA) Transcreener HTS Assays and iuvo Microconduit array technology.

Image: The Transcreener HTS Assays (Photo courtesy of BellBrook Labs).
Image: The Transcreener HTS Assays (Photo courtesy of BellBrook Labs).

Cambio is a privately held British company with a reputation for supplying high quality molecular biology reagents and consumables. To meet the needs of a growing and diversifying market, advanced molecular biology products are continually being added to the company’s portfolio.

BellBrook Labs’ Transcreener Biochemical Assay Platform was developed to move more new targets into the realm of high throughput assays and to streamline selectivity profiling within a target family. It relies on the homogenous fluorescent immunodetection of nucleotides, including ADP, UDP, GDP, AMP, and GMP, which are formed by thousands of cellular enzymes. Among these are group transferase families, such as kinases and glycosyltransferases that catalyze the covalent regulatory reactions that are central to cell signaling. Each Transcreener Assay provides a generic detection method for multiple enzyme families. This promotes the evaluation of new therapeutic strategies and optimization of lead molecules and reduces time-consuming assay development for individual targets.

Cambio also will be marketing BellBrook Labs’ iuvo MicroConduit Array Technology. These microscale cell-culture devices incorporate unique advantages for miniaturization and automation of cellular assays. MicroConduit Arrays rely on liquid displacement from microchannels rather than the cumbersome aspiration and replacement used with open wells, yet they are compatible with existing liquid dispensing equipment. Applications include invasion and migration assays and reconstruction of cells in complex three-dimensional formats that recapitulate paracrine signaling in the context of native tissue.

Related Links:
Cambio
BellBrook Labs


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
Automated Clinical Chemistry Analyzer
Envoy 500+

Latest BioResearch News

Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
23 Apr 2012  |   BioResearch

Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
23 Apr 2012  |   BioResearch

Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
23 Apr 2012  |   BioResearch



ADLM